Nanotherapeutics

Your Biopharmaceutical Development and Manufacturing Partner

Nanotherapeutics Awarded BARDA Oral Radiation Drug Contract

HHS Newsroom - September 2011

Nanotherapeutics receives $4.8 million BARDA contract to develop and improve the formulation and manufacturing processes of Diethylenetriaminepentaacetate (DTPA), a drug to treat internal contamination from radiation after a radiological attack.

Full Article

Copyright 2016 NANOTHERAPEUTICS, INC.  All rights reserved.